M P Muller1, S Junaid2, L M Matukas3. 1. Department of Medicine, St. Michael's Hospital, Toronto, ON, Canada; Infection Prevention and Control Service, St. Michael's Hospital, Toronto, ON, Canada. Electronic address: mullerm@smh.ca. 2. Infection Prevention and Control Service, St. Michael's Hospital, Toronto, ON, Canada. 3. Department of Medicine, St. Michael's Hospital, Toronto, ON, Canada; Department of Laboratory Medicine, St. Michael's Hospital, Toronto, ON, Canada.
Abstract
BACKGROUND: Both hospital admissions and patient isolation increase during influenza season. Influenza testing methodologies that reduce turnaround time (TAT) could reduce time in isolation. METHODS: We assessed the impact of a new influenza test on TAT and isolation days. TAT and daily mean isolation days were compared at a single hospital over 2 influenza seasons. An automated real-time reverse-transcription polymerase chain reaction assay (rRT-PCR) with random access replaced a conventional rRT-PCR assay for the second influenza season. Automation and random access allowed continuous testing, rather than once daily testing 3-5 d/wk. RESULTS: Confirmed influenza cases (57 vs 68) and total patient days (66,308 vs. 66,366) were similar for the 2012-2013 and 2013-2014 influenza seasons. TAT fell from 35 to 3.6 hours. Daily mean isolation days (32.9 vs 27.7, P < .01) fell, as did days in contact precautions (25.0 vs 19.8, P < .01) and droplet precautions (6.0 vs 3.5, P < .01). Although daily mean droplet precaution days for confirmed influenza rose slightly (0.86 vs 1.1, P = .16), droplet precaution days for suspected influenza fell 85% (2.7 vs 0.41, P < .001). CONCLUSIONS: Influenza testing technology that reduced TAT from days to hours resulted in a 42% reduction in droplet precaution days and reduced overall isolation days during influenza season.
BACKGROUND: Both hospital admissions and patient isolation increase during influenza season. Influenza testing methodologies that reduce turnaround time (TAT) could reduce time in isolation. METHODS: We assessed the impact of a new influenza test on TAT and isolation days. TAT and daily mean isolation days were compared at a single hospital over 2 influenza seasons. An automated real-time reverse-transcription polymerase chain reaction assay (rRT-PCR) with random access replaced a conventional rRT-PCR assay for the second influenza season. Automation and random access allowed continuous testing, rather than once daily testing 3-5 d/wk. RESULTS: Confirmed influenza cases (57 vs 68) and total patient days (66,308 vs. 66,366) were similar for the 2012-2013 and 2013-2014 influenza seasons. TAT fell from 35 to 3.6 hours. Daily mean isolation days (32.9 vs 27.7, P < .01) fell, as did days in contact precautions (25.0 vs 19.8, P < .01) and droplet precautions (6.0 vs 3.5, P < .01). Although daily mean droplet precaution days for confirmed influenza rose slightly (0.86 vs 1.1, P = .16), droplet precaution days for suspected influenza fell 85% (2.7 vs 0.41, P < .001). CONCLUSIONS: Influenza testing technology that reduced TAT from days to hours resulted in a 42% reduction in droplet precaution days and reduced overall isolation days during influenza season.
Authors: Carmen L Charlton; Esther Babady; Christine C Ginocchio; Todd F Hatchette; Robert C Jerris; Yan Li; Mike Loeffelholz; Yvette S McCarter; Melissa B Miller; Susan Novak-Weekley; Audrey N Schuetz; Yi-Wei Tang; Ray Widen; Steven J Drews Journal: Clin Microbiol Rev Date: 2018-12-12 Impact factor: 26.132
Authors: Anneloes L van Rijn; Roel H T Nijhuis; Vincent Bekker; Geert H Groeneveld; Els Wessels; Mariet C W Feltkamp; Eric C J Claas Journal: Eur J Clin Microbiol Infect Dis Date: 2017-12-08 Impact factor: 3.267
Authors: Laura M Vos; Jesper M Weehuizen; Andy I M Hoepelman; Karin H A H Kaasjager; Annelies Riezebos-Brilman; Jan Jelrik Oosterheert Journal: J Clin Virol Date: 2019-04-07 Impact factor: 3.168
Authors: Scott E Evans; Ann L Jennerich; Marwan M Azar; Bin Cao; Kristina Crothers; Robert P Dickson; Susanne Herold; Seema Jain; Ann Madhavan; Mark L Metersky; Laura C Myers; Eyal Oren; Marcos I Restrepo; Makeda Semret; Ajay Sheshadri; Richard G Wunderink; Charles S Dela Cruz Journal: Am J Respir Crit Care Med Date: 2021-05-01 Impact factor: 30.528
Authors: Laura M Vos; Andrea H L Bruning; Johannes B Reitsma; Rob Schuurman; Annelies Riezebos-Brilman; Andy I M Hoepelman; Jan Jelrik Oosterheert Journal: Clin Infect Dis Date: 2019-09-13 Impact factor: 9.079